North America pharmaceutical contract research organization (CRO) market is projected to grow by 9.0% annually in the forecast period and reach $37.61 billion by 2030, driven by the increasing incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity.
Highlighted with 59 tables and 44 figures, this 132-page report “North America Pharmaceutical Contract Research Organization Market 2021-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire North America pharmaceutical contract research organization (CRO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2030 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical contract research organization (CRO) market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Country.
Based on Service, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section.
• CRO for Pre-clinical Development
• CRO for Phase I Trials
• CRO for Phase II Trials
• CRO for Phase III Trials
• CRO for Phase IV Trials
• Laboratory Services
• Consulting Services
• Data Management Services
Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section.
• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications
By End User, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section.
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Academic Institutes
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2021-2030. The breakdown of key national markets by Service, Therapeutic Application, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co., Ltd.
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co., Ltd.
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co., Ltd.
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
For Sample Report Visit Here: https://www.rightsightresearch.com/reports/north-america-pharmaceutical-contract-research-organization-cro-market/rsr-dc893b8